NCT05858645View on ClinicalTrials.gov

Correction of Psoriatic T Cell Signatures by Deucravacitinib

PHASE4RecruitingINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Psoriasis Vulgaris

Interventions

DRUG

deucravacitinib

Treatment with deucravacitinib, skin biopsy and blood analysis pre- and mid-treatment

Trial Locations (1)

94115

RECRUITING

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT05858645 - Correction of Psoriatic T Cell Signatures by Deucravacitinib | Biotech Hunter | Biotech Hunter